Save time and get answers to complex questions with AI chat
Patent expiry trametinib?Is allopurinol expensive?Bivalirudin manufacturer?Xenazine current manufacturer 2025?What's the advised delay for milk post lipitor?
See the DrugPatentWatch profile for pembrolizumab
Pembrolizumab targets and inhibits the PD-1 receptor on T cells (CD279). It binds PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2, lifting the inhibitory PD-1 pathway to re-activate T-cell anti-tumor activity.
Other Questions About Pembrolizumab :